IBRX Revenue Up 92% But $1.19B Debt Risks Dilution
IBRX stock analysis: 121% revenue surge hits $1.19B debt — buy or sell?
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down ImmunityBio, Inc. (IBRX) and its commercial progress with FDA-approved bladder cancer therapy ANKTIVA alongside upcoming label expansions. With net product revenue growing 121% YoY in the first half of 2026 but counterbalanced by a $1.19 billion debt and revenue interest liability overhang, the key…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.